Paxil awards and settlements: Paxil and its generic equivalents have remained among the best selling antidepressants in the country since debuy-ing in 1992. In 2001 alone, manufacturer GlaxoSmithKline (GSK) sold $2.1 million worth of Paxil and in 2007, $18.1 million worth of Paroxetine prescriptions were filled. But in spite of robust sales figures, Paxil has also proven to be costly for GSK. Between the time the drug was introduced in 2009, GlaxoSmithKline paid out almost $1 billion dollars to resolve all Paxil related lawsuits, including $390 million for causing suicides or attempted suicides, $200 million dollars for causing birth defects, and $400 million for antitrust, fraud, and design claims. In 2010, GSK agreed to pay another $1.14 billion to resolve claims that Paxil caused birth defects in some users children, bringing to more than $2 billion the amount GSK has agreed to pay to resolve a variety of Paxil related suits.
Be the first to comment